Spadavecchia F.,Universitadegli Studidi Milan |
Ceotto M.,Universitadegli Studidi Milan |
Ceotto M.,Consortium for Science and Technology of Materials |
Presti L.L.,Universitadegli Studidi Milan |
And 10 more authors.
Chinese Journal of Chemistry | Year: 2014
A state-of-the-art overview of N-dopant characterizations in nano-TiO2 second-generation photocatalysts is provided. The related literature is very rich and sometimes offers contrasting interpretations. Here we critically discuss up-to-date literature results and our own findings, as retrieved by several experimental (BET, HR-TEM, XPS, DRS, HR-XRPD, EXAFS, electrochemical tools) and theoretical (periodic DFT) techniques. Our intent is to pull together outcomes from very different and complementary sources to make an as much as possible coherent picture of the morphological, electrochemical and electronic properties of N-TiO2 materials. It is commonly accepted that critical issues to be considered in the design of high-performing N-TiO2 photocatalysts are synthetic strategy, defect concentration and chemical nature of the lattice point defects. We focus on the latter two issues, with emphasis on sol-gel prepared materials, according to the specific area of expertise of our group. The problem of the chemical nature of guest N species into the lattice is crucial, as substitutional (Ns) or interstitial (Ni) nitrogen place their valence states just above the valence band or deeper into the band gap. Overall, we show how synergism among experimental and theoretical techniques is decisive to disentangle structural, electronic and morphological effects in complex N-doped TiO2 matrices. © 2014 SIOC, CAS, Shanghai, & WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. Source
Gattermann N.,Heinrich Heine University Dusseldorf |
Finelli C.,Policlinico S. Orsola Malpighi |
Della Porta M.,University of Pavia |
Fenaux P.,Paris13 University |
And 129 more authors.
Leukemia Research | Year: 2010
The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500. ng/mL, ∼50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-naïve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p<0.0001). This large dataset prospectively confirms the efficacy and well characterizes the safety profile of deferasirox in MDS. © 2010 Elsevier Ltd. Source